Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Mark Girgis, M.D.

Description

Summary

This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

Official Title

A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma

Keywords

PDAC - Pancreatic Ductal Adenocarcinoma, FAP, Fibroblast Activation Protein Inhibitor (FAPI), PDAC, Ductal Carcinoma, Pancreatic Ductal Carcinoma, FAPI-46, [68Ga]FAPI-46

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Pathologically confirmed pancreatic ductal adenocarcinoma
  2. Treatment-naïve
  3. Staged as resectable or borderline-resectable
  4. Planned to undergo surgical resection or to receive neoadjuvant therapy (i.e., chemotherapy, radiation therapy, or combination) and subsequent possible surgical resection
  5. Anatomic imaging (e.g., CT, MRI) obtained within ≤ 28 days of consent
  6. Age ≥ 18 years
  7. Completed informed consent as determined per the IRB of record

You CAN'T join if...

  1. Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of child-bearing potential
  2. Declining to use effective contraceptive methods during the study (for individuals of child-producing potential)
  3. Need for emergent surgery that would be delayed by participation
  4. Bacterial, viral, or fungal infections requiring systemic therapy
  5. Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney failure, liver failure, systemic or local inflammatory or autoimmune diseases or other conditions) that in the opinion of the investigator, physician of record and/or Sofie could compromise patient safety and/or protocol objectives.
  6. Known diagnosis of autoimmune disorders
  7. Patients receiving any other investigational agent within the past 28 days
  8. Breastfeeding. Note: nursing parents are allowed if the potential participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the [68Ga]FAPI-46 injection.
  9. Known hypersensitivity to any excipients used in [68Ga]FAPI-46:

    trace amounts of sodium acetate sodium ascorbate and/or hydrochloric acid

Locations

  • University of California Los Angeles (UCLA) Health accepting new patients
    Los Angeles California 90095 United States
  • Mayo Clinic accepting new patients
    Rochester Minnesota 55905 United States
  • BAMF Health accepting new patients
    Grand Rapids Michigan 49503 United States
  • NYU Langone Health completed
    New York New York 10016 United States

Lead Scientist at UCLA

  • Mark Girgis, M.D.
    Assistant Professor-in-Residence, Surgery, Medicine. Authored (or co-authored) 58 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
SOFIE
Links
Sign up for this study
ID
NCT05262855
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated